Also trades as: DRMA (NASDAQ) · $vol 2M
DRMAW NASDAQ
Dermata Therapeutics, Inc.
1W: +27.1%
1M: +0.0%
3M: -5.7%
YTD: -1.2%
1Y: +98.9%
$0.01
-0.00 (-9.35%)
Weekly Expected Move ±38.7%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.0M
52W Range0.0125-0.0229
Volume0
Avg Volume7,518
Beta1.29
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOGerald T. Proehl
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2021-08-13
Websitedermatarx.com
3525 Del Mar Heights Road
San Diego, CA 92130
US
San Diego, CA 92130
US
858 800 2543
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bedoya-Toro Munera M | P-Purchase | 1,000 | $1.27 | 2026-02-17 |
| Van Hoose Kyri K. | A-Award | 122,549 | — | 2025-12-23 |
| PROEHL GERALD T | A-Award | 490,196 | — | 2025-12-23 |
| PROEHL GERALD T | A-Award | 122,549 | — | 2025-12-23 |
| HALE DAVID F | A-Award | 78,741 | — | 2025-01-23 |